Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
3.679
Zitationen
14
Autoren
2004
Jahr
Abstract
The improvement in median survival of nearly two months with docetaxel and estramustine, as compared with mitoxantrone and prednisone, provides support for this approach in men with metastatic, androgen-independent prostate cancer.
Ähnliche Arbeiten
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 · 5.691 Zit.
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 · 5.435 Zit.
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 · 4.526 Zit.
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
1998 · 4.482 Zit.
Abiraterone and Increased Survival in Metastatic Prostate Cancer
2011 · 4.355 Zit.
Autoren
Institutionen
- Columbia University Irving Medical Center(US)
- Herbert Irving Comprehensive Cancer Center
- Cancer Research And Biostatistics(US)
- SWOG Cancer Research Network(US)
- University of Michigan–Ann Arbor(US)
- Michigan Center for Translational Pathology(US)
- Baylor College of Medicine(US)
- University of Massachusetts Chan Medical School(US)
- Mayo Clinic in Arizona(US)
- Neurobehavioral Systems(US)
- University of Washington(US)
- University of Arkansas for Medical Sciences(US)
- University of California, San Francisco(US)
- Cleveland Clinic(US)
- University of Colorado Hospital(US)
- University of Colorado Health(US)
- University of Colorado Denver(US)